Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Retained Earnings (2016 - 2026)

Amphastar Pharmaceuticals has reported Retained Earnings over the past 13 years, most recently at $666.9 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 17.25% year-over-year to $666.9 million; the TTM value through Dec 2025 reached $666.9 million, up 17.25%, while the annual FY2025 figure was $666.9 million, 17.25% up from the prior year.
  • Retained Earnings for Q4 2025 was $666.9 million at Amphastar Pharmaceuticals, up from -$5.3 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $666.9 million in Q4 2025 and troughed at -$9.9 million in Q3 2022.
  • A 5-year average of $217.5 million and a median of $62.7 million in 2021 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: tumbled 106.67% in 2022 and later surged 7182.51% in 2025.
  • Year by year, Retained Earnings stood at -$6.8 million in 2021, then fell by 27.48% to -$8.6 million in 2022, then soared by 4845.69% to $409.3 million in 2023, then soared by 38.98% to $568.8 million in 2024, then rose by 17.25% to $666.9 million in 2025.
  • Business Quant data shows Retained Earnings for AMPH at $666.9 million in Q4 2025, -$5.3 million in Q3 2025, and $625.1 million in Q2 2025.